medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2012, Number 3

<< Back Next >>

Rev Mex Patol Clin Med Lab 2012; 59 (3)

Phenotype value by flow cytometric in the diagnostic confirmation of plasmatic cell leukemia

Hussein AA, Valdés RY, Muñio PJE, Carnot UJ, Carballo TT, Marcel EA, Gómez LM

Language: Spanish
References: 19
Page: 134-141
PDF size: 344.37 Kb.


ABSTRACT

The leukemia of the plasmatic cells (LPC) is an infrequent variant and aggressive multiple myeloma. When one suspects of LPC they need a combination of different clinical and paraclinic indicators that permits confirmation of the presence of monoclonal tumor cells in peripheral blood. To confirm diagnosis of a 62 year old patient suspected to have LPC, they determined the phenotype of the tumor cells employing the flow cytometric method and antigens CD45+/CD38+ as markers. The information obtained by the flow cytometric method was compared to the obtained from the radiological, biochemical and morphological studies (medulogram and tumor cells count on the peripheric slide); as well as other information from the patients clinical history. With the flow cytometric method 29.25% of tumor cells were observed which confirms LCP diagnosis. The patient presented frequent bone pain, anemia syndrome and immunoglobulin (IgG). However considering the absence of renal insufficiency or other hematological affections, we have come to the conclusion of classifying LPC as a stage III according to the Durie-Salmon criteria.


REFERENCES

  1. Grogan TM, Van Camp B, Kyle RA, Müller-Hermelink HK, Harris NL. Pathology and genetics of tumors of haemato-poietc and lymphoid tissues. In: Grogan TM et al (eds). World Health Organization Classification of Tumors (WHO): Plasma cell neoplasm. Lyon: IARC Press. 2001. p. 142-156.

  2. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press. 2001. p. 142-147.

  3. Kyle AR. The international Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: Brit J Haematol 2003; 121: 749-757.

  4. Ioannou MG, Stathakis E, Lazaris AC et al. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses. Blood 2008; 111: 3941.

  5. Van Camp B, Vanderkerken K, Bakkus M, Van Riet I. New insights into myeloma biology. En: Sesión 3 del 5o Congreso de la Asociación Hematológica Europea. Birmingham, UK. 2000. Disponible en: http://listis.mmsupport.net

  6. Papayannopoulou T, Priestley GV, Nakamoto B et al. Molecular pat5hways in bone marrow homing: Dominant role of alpha 4 beta 1 over beta 2 integrins and selecyins. Blood 2001; 98: 2403.

  7. Costelo R, Sainty D, Bouabdallah R, Fermand J, Delmer A, Rousselot P, Chaibi P. Primary Plasma Cell Leukemia: A report of 18 cases. Leukemia Research 2001; 25: 103-107.

  8. Noel P, Kyle RA. Plasma cell leukemia: An evaluation of response to therapy. Am J Med 1987; 83: 1062.

  9. Yamamoto, JF, Goodman, MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19: 379.

  10. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13: 1259.

  11. Tiedemann RE, Gonzalez-Paz, N, Kyle RA et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22: 1044.

  12. Zeppa P, Marino G, Troncone G, Fulciniti F et al. Fine needle cytology and Flow Cytometry immunophenotyping andsubclassification of Non-Hodgkin Lymphoma. Cancer Cytopathology 2004; 102 (1): 55-65.

  13. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol 2005; 132: 410-451.

  14. IMWG. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.

  15. Berenson JR. Myeloma bone disease. Best Pract Res Clin Haematol 2005; 18 (4): 653–672.

  16. Dispenzieri A, Kyle RA. Multiple myeloma: Clinical features and indications for therapy. Best Pract Res Clin Haematol 2005; 18 (4): 553-568.

  17. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 2003; 194: 112-139.

  18. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36 (3): 842-854.

  19. Garcia-Sanz R, Orfao A, González M et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 2001; 97: 822.




2020     |     www.medigraphic.com